title: Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells.
abstract: The use of tumor cells as vaccines in cancer immunotherapy is critically dependent on their capacity to initiate and amplify tumor-specific immunity. Optimal responses may require the modification of the tumor cells not only to increase their immunogenicity but also to improve their ability to recruit effector cells to the tumor sites or sites of tumor antigen exposure. It has been reported that CD40 cross-linking of acute lymphoblastic leukemia (ALL) cells significantly increases their immunogenicity and allows the generation and expansion of autologous antileukemia cytotoxic T lymphocytes. This study demonstrates that the CD40 ligation of these tumor cells also induces the secretion of the CC-chemokines MDC and TARC. Supernatants from malignant cells cultured in the presence of sCD40L promote the migration of activated T cells that express CCR4, the common specific receptor for MDC and TARC. More importantly, the supernatants from CD40-stimulated tumor cells also support the transendothelial migration of autologous CCR4(+) antileukemia T cells. Therefore, the results demonstrate that the delivery to leukemia cells of a single physiologic signal, that is, CD40 cross-linking, simultaneously improves tumor cell immunogenicity and induces potent chemoattraction for T cells. (Blood. 2001;98:533-540)
authors.affiliation: Department of Adult Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
authors.forename: P
authors.initials: P
authors.lastname: Ghia
authors.forename: P
authors.initials: P
authors.lastname: Transidico
authors.forename: J P
authors.initials: JP
authors.lastname: Veiga
authors.forename: C
authors.initials: C
authors.lastname: Schaniel
authors.forename: F
authors.initials: F
authors.lastname: Sallusto
authors.forename: K
authors.initials: K
authors.lastname: Matsushima
authors.forename: S E
authors.initials: SE
authors.lastname: Sallan
authors.forename: A G
authors.initials: AG
authors.lastname: Rolink
authors.forename: A
authors.initials: A
authors.lastname: Mantovani
authors.forename: L M
authors.initials: LM
authors.lastname: Nadler
authors.forename: A A
authors.initials: AA
authors.lastname: Cardoso
mesh_terms: D017951:Antigen Presentation; D000951:Antigens, Neoplasm; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D002051:Burkitt Lymphoma / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D019013:CD40 Antigens / Q000378:metabolism*; D023201:CD40 Ligand / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects*; D054414:Chemokine CCL17; D054422:Chemokine CCL22; D019742:Chemokines, CC / Q000378:metabolism* / Q000494:pharmacology; D002630:Chemotactic Factors / Q000378:metabolism / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D011485:Protein Binding; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000187:drug effects / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; C106230:CCL17 protein, human; C515482:CCL22 protein, human; D019013:CD40 Antigens; D054414:Chemokine CCL17; D054422:Chemokine CCL22; D019742:Chemokines, CC; D002630:Chemotactic Factors; D023201:CD40 Ligand